Clinical Trials | February 17, 2026
Teva and Sanofi duvakitug Phase 2b data show sustained efficacy in IBD
Duvakitug was well tolerated and safety was consistent with the induction study
Duvakitug was well tolerated and safety was consistent with the induction study
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Garijo will be the first woman to lead Sanofi in its history
Subscribe To Our Newsletter & Stay Updated
